Clinical Trials
33 trialsNCT07585734 2026-05-14
Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT07328490 2026-04-28
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT02856503 2026-04-17
Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors
University of Miami
Phase 1/2 Withdrawn
NCT05664893 2026-04-15
CALHYS
Centre Antoine Lacassagne
Phase 1/2 Withdrawn
NCT06767956 2026-04-13
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
Phase 1/2 Withdrawn
NCT06434103 2026-04-08
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Withdrawn
NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
NCT05982522 2026-03-27
IN10018 Combination Therapy in Previously-treated Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Withdrawn
NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT06284460 2026-02-13
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT06545617 2026-01-07
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
Phase 1/2 Withdrawn
NCT07071909 2026-01-06
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT04129515 2026-01-02
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Brown University
Phase 1/2 Withdrawn
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT05668949 2025-12-17
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT06005649 2025-08-08
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT06009107 2025-08-08
B-ALL
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT05678205 2025-07-30
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT02264236 2025-07-20
Vaccination of Advanced-Stage Lung Cancer Patients
University of Arkansas
Phase 1/2 Withdrawn
NCT05879484 2025-07-10
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT05538988 2025-06-27
BIOSELECT
AHS Cancer Control Alberta
Phase 1/2 Withdrawn
NCT05687721 2025-06-15
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
VA Office of Research and Development
Phase 1/2 Withdrawn
NCT06592664 2025-06-06
FORTIFIDE
Lisata Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn